Tudor Investment Corporation »

Arrivent Biopharma shares owned by Tudor Investment Corporation

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Tudor Investment Corporation from 13F filings

Historical chart of Tudor Investment Corporation investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Tudor Investment Corporation consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Tudor Investment Corporation

Quarter filed Position value Share count Share price at filing
2026-03-31 $510k 22k 23.07
2025-03-31 $283k 15k 18.49

More positions owned by Tudor Investment Corporation

Ishares Russell 2000 Etf - US ETP ETF Option Call Option (IWM)
Invesco Qqq Trust Series 1 - US ETP ETF Option Call Option (QQQ)
State Street SPDR S&P 500 ETF Trust - US ETP ETF Option Call Option (SPY)
Spdr Gold Shares - US ETP ETF Option Call Option (GLD)
Nvidia Corp - US Equity (NVDA)
State Street Energy Select Sector SPDR ETF - US ET ETF Option Call Option (XLE)
Ishares Msci Emerging Markets Etf - US ETP ETF Option Call Option (EEM)
Microsoft Corp - US Equity (MSFT)
State Street Financial Select Sector SPDR ETF - US ETF Option Call Option (XLF)
Tesla Inc - US Equity (TSLA)
Ishares China Large-Cap Etf - US ETP ETF Option Call Option (FXI)
Meta Platforms Inc - US Equity (META)
Taiwan Semiconductor Manufacturing Co Ltd - US Depository Receipt (TSM)
Alibaba Group Holding Ltd - US Depository Receipt (BABA)
Amazon.Com Inc - US Equity (AMZN)

View all positions for Tudor Investment Corporation

Top funds holding Arrivent Biopharma

Suvretta Capital Management
Infinitum Asset Management
Hillhouse Capital Advisors
OrbiMed Advisors
FMR
BlackRock
Octagon Capital Advisors
Novo A/S
Vanguard Group
Sofinnova Ventures
Vanguard Capital Management
General Catalyst Group Management
State Street Corporation
Vivo Capital
Goldman Sachs Group

View all funds holding Arrivent Biopharma